Decreased Levels of MiR-126 and MiR-132 in Plasma and Vitreous Humor of Non-Proliferative Diabetic Retinopathy Among Subjects with Type-2 Diabetes Mellitus

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2022 Feb 14

PMID 35153496

Authors

Subhasish Pramanik

Chinmay Saha

Subhankar Chowdhury

Chiranjit Bose

Nitai P Bhattacharyya

Lakshmi Kanta Mondal

Affiliations

Soon will be listed here.

Abstract

Purpose: Diabetic retinopathy (DR), the leading cause of blindness among working adults, is an urgent public health problem as diabetes mellitus (DM) is increasing at an alarming rate. Hyperglycemia-induced endothelial dysfunction is the principal contributing factor leading to the development of microangiopathy. Altered levels of microRNA (miR), the negative regulator of protein-coding genes, have been observed and considered to be markers for DR. Present study aimed to find out whether miR levels in plasma could be effective biomarkers to differentiate between type 2 diabetes mellitus (T2DM) with non-proliferative retinopathy (NPDR) from T2DM with no-DR (DNR).

Methods: We recruited 50 T2DM subjects comprising 31 NPDR and 19 DNR individuals. Surrogate markers of systemic oxidative stress and vascular endothelial growth factor (VEGF) were measured in plasma. Levels of miR-126 and miR-132 were determined in plasma and vitreous fluid using real-time PCR.

Results: We observed that levels of miR-126 and miR-132 were decreased in NPDR subjects in comparison to DNR. Plasma levels of miRs were inversely correlated with secreted levels of VEGF and oxidative stress marker. The levels of these miRs showed discriminating ability between NPDR and DNR.

Conclusion: Circulating miRs 126 and 132 in plasma or vitreous may serve as biomarkers for early diabetic retinopathy risk prediction, provided validated in a larger cohort and other forms of retinal vasculopathy or retinopathy in the future.

Citing Articles

Microvesicle-associated and circulating microRNAs in diabetic dyslipidemia: miR-218, miR-132, miR-143, and miR-21, miR-122, miR-155 have biomarker potential.

Nemecz M, Stefan D, Comarita I, Constantin A, Tanko G, Guja C Cardiovasc Diabetol. 2023; 22(1):260.

PMID: 37749569 PMC: 10521428. DOI: 10.1186/s12933-023-01988-0.

Oxidative Stress and Its Regulation in Diabetic Retinopathy.

Haydinger C, Oliver G, Ashander L, Smith J Antioxidants (Basel). 2023; 12(8).

PMID: 37627644 PMC: 10451779. DOI: 10.3390/antiox12081649.

Mechanisms of MALAT1 regulating proliferative diabetic retinopathy via targeting miR-126-5p.

Zhao W, Liu Y, Li C, Yin Z, Liu Y, An M Am J Transl Res. 2023; 15(5):3279-3289.

PMID: 37303661 PMC: 10251023.

Tissue nanotransfection causes tumor regression by its effect on nanovesicle cargo that alters microenvironmental macrophage state.

Gordillo G, Guda P, Singh K, Biswas A, Abouhashem A, Rustagi Y Mol Ther. 2022; 31(5):1402-1417.

PMID: 36380587 PMC: 10188642. DOI: 10.1016/j.ymthe.2022.11.003.

References

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Beltramo E, Porta M . Pericyte loss in diabetic retinopathy: mechanisms and consequences. Curr Med Chem. 2013; 20(26):3218-25. DOI: 10.2174/09298673113209990022. View

Wang W, Lo A . Diabetic Retinopathy: Pathophysiology and Treatments. Int J Mol Sci. 2018; 19(6). PMC: 6032159. DOI: 10.3390/ijms19061816. View

Patel J, Hykin P, Gregor Z, Boulton M, Cree I . Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol. 2005; 89(4):480-3. PMC: 1772595. DOI: 10.1136/bjo.2004.049940. View

Zhang Q, Fang W, Ma L, Wang Z, Yang Y, Lu Y . VEGF levels in plasma in relation to metabolic control, inflammation, and microvascular complications in type-2 diabetes: A cohort study. Medicine (Baltimore). 2018; 97(15):e0415. PMC: 5908634. DOI: 10.1097/MD.0000000000010415. View

Ye P, Liu J, He F, Xu W, Yao K . Hypoxia-induced deregulation of miR-126 and its regulative effect on VEGF and MMP-9 expression. Int J Med Sci. 2014; 11(1):17-23. PMC: 3880987. DOI: 10.7150/ijms.7329. View

Nallamshetty S, Chan S, Loscalzo J . Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol Med. 2013; 64:20-30. PMC: 3762925. DOI: 10.1016/j.freeradbiomed.2013.05.022. View

Wang J, Yao Y, Wang K, Li J, Chu T, Shen H . MicroRNA-148a-3p alleviates high glucose-induced diabetic retinopathy by targeting TGFB2 and FGF2. Acta Diabetol. 2020; 57(12):1435-1443. DOI: 10.1007/s00592-020-01569-7. View

Liu H, Li X, Wu N, Tong M, Chen S, Zhu S . Serum microRNA-221 as a biomarker for diabetic retinopathy in patients associated with type 2 diabetes. Int J Ophthalmol. 2018; 11(12):1889-1894. PMC: 6288522. DOI: 10.18240/ijo.2018.12.02. View

10.

Zampetaki A, Willeit P, Burr S, Yin X, Langley S, Kiechl S . Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes. Diabetes. 2015; 65(1):216-27. DOI: 10.2337/db15-0389. View

11.

Cheung N, Mitchell P, Wong T . Diabetic retinopathy. Lancet. 2010; 376(9735):124-36. DOI: 10.1016/S0140-6736(09)62124-3. View

12.

Qin L, An M, Liu Y, Xu H, Lu Z . MicroRNA-126: a promising novel biomarker in peripheral blood for diabetic retinopathy. Int J Ophthalmol. 2017; 10(4):530-534. PMC: 5406628. DOI: 10.18240/ijo.2017.04.05. View

13.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

14.

Platania C, Maisto R, Trotta M, DAmico M, Rossi S, Gesualdo C . Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach. Br J Pharmacol. 2019; 176(13):2179-2194. PMC: 6555853. DOI: 10.1111/bph.14665. View

15.

Desjarlais M, Rivera J, Lahaie I, Cagnone G, Wirt M, Omri S . MicroRNA expression profile in retina and choroid in oxygen-induced retinopathy model. PLoS One. 2019; 14(6):e0218282. PMC: 6561584. DOI: 10.1371/journal.pone.0218282. View

16.

Fang S, Ma X, Guo S, Lu J . MicroRNA-126 inhibits cell viability and invasion in a diabetic retinopathy model via targeting IRS-1. Oncol Lett. 2017; 14(4):4311-4318. PMC: 5604121. DOI: 10.3892/ol.2017.6695. View

17.

Rangasamy S, Srinivasan R, Maestas J, McGuire P, Das A . A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011; 52(6):3784-91. PMC: 3109054. DOI: 10.1167/iovs.10-6386. View

18.

Mondal L, Bhaduri G, Bhattacharya B . Biochemical scenario behind initiation of diabetic retinopathy in type 2 diabetes mellitus. Indian J Ophthalmol. 2018; 66(4):535-540. PMC: 5892057. DOI: 10.4103/ijo.IJO_1121_17. View

19.

Wang M, Zheng H, Zhou X, Zhang J, Shao G . miR-122 promotes diabetic retinopathy through targeting TIMP3. Anim Cells Syst (Seoul). 2020; 24(5):275-281. PMC: 7646554. DOI: 10.1080/19768354.2020.1816580. View

20.

Wilkinson C, Ferris 3rd F, Klein R, Lee P, Agardh C, Davis M . Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003; 110(9):1677-82. DOI: 10.1016/S0161-6420(03)00475-5. View